Peter Aronstram

Peter Aronstram

CFO

Peter Aronstam is our Chief Financial Officer. Mr. Aronstam brings more than 30 years of experience in accounting, finance, banking, international trade and law to his clients. His career is marked by a progression of senior finance roles with growth and performance-driven enterprises, from start-up technology and Internet companies to chief financial officer roles with small service providers to very large international manufacturers to global banks.
Noreen Griffin

Noreen Griffin

CEO

Noreen Griffin is one of our Founders, our CEO and a member of our Board of Directors. Ms. Griffin was a vital part of the acquisition of our patents and therapies involving Methionine [ Met5]-enkephalin (MENK) and low-dose naltrexone (LDN). She was involved with the inventors and patent holders for over five years before deciding to join the team that formed our company. Ms. Griffin has over 25 years of industry experience, having founded and led a number of startup companies. She has played an integral role in raising multiple rounds of private and venture capital funds on behalf of clients. Ms. Griffin has served as Chief Financial Officer and Vice President of a number of small public companies over the last 10 years. In addition, Ms. Griffin has significant experience in the administration of companies in bankruptcies.
Dr. Fengpin Shan

Dr. Fengpin Shan

CSO

Dr. Fengping Shan is our Chief Science Officer and a former member of our Board of Directors. Dr. Shan has a Ph.D. in Microbiology and Tumor Immunology. Dr. Shan is Professor of Immunology and Vice Director of the Institute of Immunology, China Medical University, in Shenyang, China. Professor Shan has been with the University from 2006 to present.